4-(Hexylamino)-4-oxobutanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(Hexylamino)-4-oxobutanoic acid
• 化学式: C₁₀H₁₉NO₃
• mdl: MFCD00517733
• 分子量: 201.26
• InChiKey: ZRQYQCSFTIVKRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Aluminium carboxylates
  申请人：STEPAN COMPANY

  公开号：EP0220934A2

  公开（公告）日：1987-05-06

  The present invention relates to a method of providing on a surface an active and/or hydrophobic coating which comprises applying to said surface a coating of an organoaluminium compound of the formula wherein R represents an amido carboxyl moiety selected from the group consisting of: or wherein Rl and R2 may be the same or different and are selected from the group consisting of hydrogen, an alkyl radical of rom 1 to about 20 carbon atoms, an aryl or aralkyl radical of from 6 to about 20 carbon atoms, and an alkenyl radical of from 3 to about 20 carbon atoms; R3 is a hydrocarbyl radical of from 1 to about 6 carbon atoms; and the sum of the carbon atoms in R' and R2 is in the range of from 0 to about 40, and the sum of the carbon atoms in R1, R2 and R3 is at least 2; R" is a modifier moiety selected from the group consisting of hydroxyl, an alkoxy radical of from 1 to about 6 carbon atoms, or carboxyl radical of from 1 to about 6 carbon atoms; R' comprises either a group as defined for R, which may be the same or different from R, or an active moiety, said active moiety being bonded to the aluminium by a carboxylate, sulphonate, phosphate, phosphite, oxa or thia linkage.

  本发明涉及一种在表面上提供活性和/或疏水涂层的方法，该方法包括在所述表面上涂敷一 层式如下的有机铝化合物涂层 其中 R 代表选自以下组别的氨基羧基 或 其中 Rl 和 R2 可以相同或不同，且选自由氢、1-约 20 个碳原子的烷基、6-约 20 个碳原子的芳基或芳烷基、3-约 20 个碳原子的烯基组成的组；R3 是 1-约 6 个碳原子的烃基；R'和 R2 中的碳原子之和在 0-约 40 的范围内，且 R1、R2 和 R3 中的碳原子之和至少为 2；R "是从羟基、1 至约 6 个碳原子的烷氧基或 1 至约 6 个碳原子的羧基组成的组中选出的改性剂分子；R'包括一个如 R 所定义的基团（可与 R 相同或不同）或一个活性分子，所述活性分子通过羧酸根、磺酸根、磷酸根、亚磷酸根、氧杂环或硫杂环键与铝结合。
• A pharmaceutical composition for use in treating an ocular disease or condition and a method for producing the composition
  申请人：Allergan, Inc.

  公开号：EP2425816A2

  公开（公告）日：2012-03-07

  The present invention provides a pharmaceutical composition for use in treating an ocular disease or condition, the composition comprising: a chitosan composition comprising a treated chitosan, a modified chitosan, a modified and treated chitosan or a mixture thereof, each modified and/or treated chitosan exhibiting a different chemical, physical and/or performance property or characteristic relative to the corresponding unmodified/untreated chitosan, and a therapeutic agent selected from a corticosteroid and a mixture of corticosteroids; wherein: each treated chitosan is obtained by dialyzing chitosan against water and a salt and/or anionic solution, and each modified chitosan is obtained by one or more of covalent attachment of one or more functional groups to chitosan, non-covalent association of one or more atomic or molecular agents with chitosan and coaddition of one or more atomic or molecular agents with chitosan, the therapeutic agent is covalently bonded to at least one treated and/or modified chitosan directly or via a linker, and the chitosan composition is adapted to release a therapeutically effective amount of the therapeutic agent over a period of time. A process for manufacturing the pharmaceutical composition is also provided, the process comprising contacting the above chitosan composition with a therapeutically-effective amount of the above therapeutic agent under conditions such that the therapeutic agent is covalently bonded to at least one treated and/or modified chitosan.

  本发明提供了一种用于治疗眼部疾病或病症的药物组合物，该组合物包括 壳聚糖组合物，包括经处理的壳聚糖、经改性的壳聚糖、经改性和处理的壳聚糖或其混合物，相对于相应的未改性/未处理的壳聚糖，每种经改性和/或处理的壳聚糖表现出不同的化学、物理和/或性能特性，以及 选自皮质类固醇和皮质类固醇混合物的治疗剂； 其中 每种处理过的壳聚糖是通过将壳聚糖与水和盐及/或阴离子溶液透析而获得的，每种改性壳聚糖是通过将一种或多种官能团共价连接到壳聚糖、一种或多种原子或分子剂与壳聚糖的非共价结合以及一种或多种原子或分子剂与壳聚糖的共添加而获得的、 治疗剂直接或通过连接体与至少一种经处理和/或修饰的壳聚糖共价键合，以及 壳聚糖组合物能够在一段时间内释放治疗有效量的治疗剂。 还提供了一种制造药物组合物的工艺，该工艺包括在使治疗剂与至少一种经处理和/或修饰的壳聚糖共价键合的条件下，将上述壳聚糖组合物与治疗有效量的上述治疗剂接触。
• NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME
  申请人：ALLERGAN, INC.

  公开号：EP2114370A2

  公开（公告）日：2009-11-11
• ANTI-EGFR ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：EP3468996B1

  公开（公告）日：2022-05-04
• NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME
  申请人：Utecht Ronald E.

  公开号：US20080200948A1

  公开（公告）日：2008-08-21

  Novel biomaterials are disclosed having unique properties that make it a useful material in adhesives, local drug delivery applications and as filler or bulking material. The biomaterials are strong, safe and easily used as a surgical adhesive. Treated chitosan, modified chitosan or modified and treated chitosan compositions are disclosed displaying strengths suitable for general surgical applications. The materials can be used as a drug delivery vehicle which allows for the localization of the delivered drug as well as a programmable tether which allows for the release of the drug on a timed basis or in response to a physiological state such as the release of proteolytic enzymes. The materials of this invention can also be modified and treated to optimize the retention of water, thereby serving as a useful filler or bulking material.